ABSTRACT
The authors wish to make the following corrections to this paper [...].
ABSTRACT
OBJECTIVE: ABO mismatch between donor and recipient occurs in 40% of allogeneic hematopoietic stem cell transplantations (HCT). Different strategies have been described to reduce isohemagglutinins (IHA) before HCT. We describe the effect of selective ABO immunoadsorption (ABO IA) on erythrocyte transfusion rate and the development of post-transplant pure red cell aplasia (ptPRCA). METHODS: 63 patients with major ABO incompatibility were retrospectively analyzed. Nine patients with major ABO incompatibility and high-IHA titer were treated by ABO IA before HCT. We analyzed the need for transfusion and the occurrence of ptPRCA. We compared the outcome with patients treated by other methods to reduce IHA. RESULTS: In all nine patients treated by ABO IA, IHA decreased in a median four times. PtPRCA occurred in one patient. The median number of transfusions was 8 (range: 0-36) between d0 and d100. In 25 patients with high-IHA titer without treatment or treated by other methods to reduce IHA, the need for transfusions was comparable. No difference in the incidence of ptPRCA was observed. CONCLUSIONS: Selective ABO IA is a feasible, safe, and effective method to reduce IHA before HCT in major ABO incompatibility. No effect on transfusion rate or ptPRCA compared to other strategies could be observed.
Subject(s)
Hematopoietic Stem Cell Transplantation/methods , Leukemia/therapy , Myelodysplastic Syndromes/therapy , Myeloproliferative Disorders/therapy , Plasmapheresis/methods , Red-Cell Aplasia, Pure/prevention & control , Transfusion Reaction/prevention & control , ABO Blood-Group System/immunology , Blood Group Incompatibility/immunology , Blood Group Incompatibility/mortality , Blood Group Incompatibility/therapy , Erythrocyte Transfusion/adverse effects , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukemia/immunology , Leukemia/mortality , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Myelodysplastic Syndromes/mortality , Myeloproliferative Disorders/immunology , Myeloproliferative Disorders/mortality , Red-Cell Aplasia, Pure/etiology , Red-Cell Aplasia, Pure/immunology , Red-Cell Aplasia, Pure/mortality , Retrospective Studies , Survival Analysis , Tissue Donors , Transfusion Reaction/etiology , Transfusion Reaction/immunology , Transfusion Reaction/mortality , Transplantation, Homologous , Treatment OutcomeABSTRACT
Side effects on cardiac ion channels causing lethal arrhythmias are one major reason for drug withdrawals from the market. Field potential (FP) recording from cardiomyocytes, is a well-suited tool to assess such cardiotoxic effects of drug candidates in preclinical drug development, but it is currently limited to the spontaneous beating of the cardiomyocytes and manual analysis. Herein, we present a novel optogenetic cardiotoxicity screening system suited for the parallel automated frequency-dependent analysis of drug effects on FP recorded from human-induced pluripotent stem cell-derived cardiomyocytes. For the expression of the light-sensitive cation channel Channelrhodopsin-2, we optimised protocols using virus transduction or transient mRNA transfection. Optical stimulation was performed with a new light-emitting diode lid for a 96-well FP recording system. This enabled reliable pacing at physiologically relevant heart rates and robust recording of FP. Thereby we detected rate-dependent effects of drugs on Naâº, Ca2+ and K⺠channel function indicated by FP prolongation, FP shortening and the slowing of the FP downstroke component, as well as generation of afterdepolarisations. Taken together, we present a scalable approach for preclinical frequency-dependent screening of drug effects on cardiac electrophysiology. Importantly, we show that the recording and analysis can be fully automated and the technology is readily available using commercial products.
